The collaboration combines Sonrai’s AI-driven multi-modal data management and analysis platform with Paige’s proprietary foundation models to accelerate precision medicine research.

Through the partnership, researchers and biopharma teams will be able to use cutting-edge AI, machine learning, and multi-modal data integration, regardless of technical expertise.

Author: Gerard Kelly

Sonrai Analytics (Sonrai), a leading AI precision medicine company accelerating the development of therapeutics through advanced analytics, and Paige, a leader in next-generation AI technology, today announced a strategic partnership to better enable biopharma researchers, pathologists, and clinicians to harness cutting-edge AI capabilities for precision medicine research and development. By integrating Paige’s state-of-the-art foundation models with Sonrai’s intuitive cloud-based data analysis and bioinformatics platform, the partnership makes AI, machine learning, and multi-modal data integration accessible to non-technical users, creating the ability for more organizations to access a wide range of critical R&D needs without requiring deep AI expertise. This important collaboration will help bring a powerful set of solutions to the market that can accelerate drug discovery, biomarker identification, targeted therapeutics and precision medicine applications.

Sonrai’s flagship product, Sonrai Discovery, expedites the identification and development of therapeutic targets, improving patient outcomes through AI. The Sonrai Discovery platform supports the integration and analysis of diverse datasets, including multi-omics (such as transcriptomics, proteomics, etc.), imaging, and clinical data. Through this partnership, the platform will incorporate Paige’s multi-modal foundation model suite, allowing biotechnology and pharmaceutical companies to manage and analyze their precision medicine data while supporting no-code applications for non-technical users. Paige’s Foundation models are considered to be state-of-the-art, built on enormous pathologic and genomic data sets, generalizable, and they are already accelerating the development of a growing portfolio of prognostic and predictive markers.

“We are thrilled to partner with Paige to unlock new possibilities for biopharma researchers and clinicians”, said Prof. Darragh McArt, CEO and Founder, Sonrai Analytics. “By combining our Sonrai Discovery platform with Paige’s foundation models, we are making AI and machine learning more accessible, enabling researchers to extract deeper insights from their data and accelerate precision medicine breakthroughs.”

“Our goal has always been to build best-in-class AI technology that is accessible to as many users as possible”, said Razik Yousfi, CEO and CTO at Paige. “Our partnership with Sonrai further drives this vision, providing a wider audience of researchers access to Paige’s Foundation Models through the Sonrai Discovery Platform. This will ultimately accelerate Pharma research and discovery globally, accelerating the new wave of AI driven biomarkers in cancer and other diseases.”

This partnership represents a significant step toward making AI-powered research more accessible, advancing the development of novel treatments and improving patient outcomes.

Sonrai and Paige will host an exclusive live webinar on 29 May 2025, titled “Unlocking Prognostic Biomarkers: Integrating Imaging and Omics with Foundation Models.” The session will explore how the convergence of imaging and omics data with advanced AI foundation models is accelerating biomarker discovery and shaping the future of precision medicine. Attendees will gain insight into real-world applications, see a live demonstration of the technology in action, and have the opportunity to engage directly with industry experts during an interactive Q&A. Registration is now open at https://bit.ly/foundation-models-webinar.

About Sonrai Analytics

Sonrai Analytics, founded in 2018, is an AI precision medicine technology company. Sonrai’s flagship product, Sonrai Discovery, expedites identifying and developing drug or therapeutic targets, improving patient outcomes through AI. The company partners with biotechnology and pharmaceutical companies to manage and analyze their precision medicine data. By leveraging Sonrai Discovery, these companies can confidently select compounds with the highest potential for success in clinical trials, accelerating drug development and mitigating the risk of failures during human trials.

With a proven track record, Sonrai has successfully deployed its technology with prominent healthcare businesses across the EU and the US. Additionally, Sonrai continues to forge strategic partnerships (including NHS) that will further enhance commercial operations and scale impact.

About Paige

Paige is pushing the boundaries of AI to solve cancer’s most critical issues, revolutionizing cancer care with next-generation technology. By leveraging exclusive access to millions of digitized pathology slides, clinical reports, and genomic data, Paige gains a holistic understanding of cancer, encompassing diverse factors such as gender, race, ethnicity, and geographical regions. This comprehensive data enables Paige to create advanced AI solutions that redefine cancer detection, diagnosis, and treatment. With a unique, intricate understanding of tissue, Paige sets new standards in precision diagnostics, earning the distinction of being the first FDA-cleared AI application in pathology. Paige has also developed the first million-slide foundation model for cancer, continuing to lead the way in uncovering novel insights and transforming them into life-changing products. For more information, visit Paige’s company showcase.